Amorfix sheep scrapie results from blinded panels presented at international Prion Conference



    TSX: AMF

    TORONTO, Oct. 8 /CNW/ - Amorfix Life Sciences, a company focused on
treatments and diagnostics for brain wasting diseases, today announced that
Dr. Neil Cashman, Chief Scientific Officer of Amorfix, will present a poster
describing the sheep scrapie results from two blinded sheep scrapie panels
using Amorfix's prototype EP-TSE(TM) Blood Screening Assay at the Prion 2008
Conference today in Madrid, Spain. The presentation entitled, "Detection of
prions in blood from asymptomatic scrapie sheep using Epitope Protection
technology" highlights the sensitivity and specificity of the EP-TSE(TM) sheep
scrapie assay.
    Dr. Philip Minor, Head of Virology Division of the National Institute for
Biological Standards and Control (NIBSC), the UK agency that prepared the
blinded panels, will also present blinded panel results for Amorfix's
EP-vCJD(TM) Blood Screening Assay and the more recent sheep scrapie results in
his presentation entitled "Blood based assays for infection with the agent of
vCJD".
    "There are approximately 100 million blood donations collected every year
and blood transfusion services outside of Europe must reject donors who have
traveled in Europe during the BSE outbreak. All countries struggle to collect
enough blood and our test for vCJD would allow more people to be blood donors
and stabilize the blood system worldwide," said Dr. George Adams, Chief
Executive Officer of Amorfix. "We continue to work closely with NIBSC and the
UK National Blood Service with the goal of testing human vCJD patient blood
samples for final assay validation."
    Scrapie is an infectious prion disease in sheep similar to Mad Cow
disease (BSE) in cattle but without the known transmission risk to humans of
BSE. Amorfix developed its sheep scrapie prion-detection assay to support the
commercialization of its leading EP-vCJD(TM) Blood Screening Assay currently
in late stage product validation. Due to the low number of blood samples from
people who have suffered from vCJD being available for large scale assay
validation, the UK government requires manufacturers to demonstrate that their
blood screening technology can detect prions in an animal model of the
disease. Amorfix tested samples from two NIBSC blinded panels of normal and
scrapie sheep that were symptomatic for the disease to show that the test can
differentiate between normal sheep and sheep with prion disease.

    About Amorfix

    Amorfix Life Sciences Ltd. (TSX:AMF) is a theranostics company developing
therapeutic products and diagnostic devices targeting brain-wasting diseases
including ALS, Alzheimer's Disease, Parkinson's Disease and variant
Creutzfeldt-Jakob Disease (vCJD). Amorfix's proprietary Epitope Protection(TM)
(EP) technology enables it to specifically identify very low levels of
aggregated misfolded proteins (AMP) in a sample of normal protein. Aggregated
misfolded proteins are a common element of many brain wasting diseases and the
ability to identify AMPs and understand their structure and mechanism of
folding are the first steps to developing new treatments for these devastating
diseases. Amorfix's lead programs are a diagnostic blood screening test for
vCJD and a therapy for ALS.

    This information release may contain certain forward-looking information.
Such information involves known and unknown risks, uncertainties and other
factors that may cause actual results, performance or achievements to be
materially different from those implied by statements herein, and therefore
these statements should not be read as guarantees of future performance or
results. All forward-looking statements are based on the Company's current
beliefs as well as assumptions made by and information currently available to
it as well as other factors. Readers are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the date of this
press release. Due to risks and uncertainties, including the risks and
uncertainties identified by the Company in its public securities filings,
actual events may differ materially from current expectations. The Company
disclaims any intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or
otherwise.

    %SEDAR: 00022789E




For further information:

For further information: Dr. George Adams, President & Chief Executive
Officer, Amorfix Life Sciences Ltd., Tel: (416) 847-6959, Fax: (416) 847-6899,
george.adams@amorfix.com; James Parsons, Chief Financial Officer, Amorfix Life
Sciences Ltd., Tel: (416) 847-6929, Fax: (416) 847-6899,
james.parsons@amorfix.com

Organization Profile

Amorfix Life Sciences Ltd.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890